[A13-04] Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 20.08.2020
Project no.:
A13-04
Commission:
Commission awarded on 14.01.2013 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-55 | Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20 August 2020: The G-BA’s decision of 21 February 2019 was cancelled.
G-BA documents on this decision